Katrien M J Devreese1,2. 1. Department of Laboratory Medicine, Coagulation Laboratory, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium. Katrien.devreese@uzgent.be. 2. Department of Diagnostic Sciences, Ghent University, Ghent, Belgium. Katrien.devreese@uzgent.be.
Abstract
PURPOSE OF THE REVIEW: This review focuses on the laboratory tests necessary for the diagnosis of antiphospholipid syndrome (APS). For the interpretation of the results of the tests for antiphospholipid antibodies (aPL), understanding of all pitfalls and interferences is necessary. RECENT FINDINGS: Progress has been made on the standardization of aPL tests and current guidelines for detection of lupus anticoagulant (LAC), anticardiolipin antibodies (aCL), and antibeta2-glycoprotein I antibodies (aβ2GPI) are useful tools. LAC measurement remains a complex procedure with many pitfalls and interference by anticoagulant therapy. Solid phase assays for aCL and aβ2GPI still show inter-assay differences. Measuring LAC, aCL, and aβ2GPI allows making antibody profiles that help in identifying patients at risk. Other aPL, such as antibodies against domain I of beta2-glycoprotein I (aDI) and antiphosphatidylserine-prothrombin (aPS/PT) antibodies, may be useful in risk stratification of APS patients, but are not included in the current diagnostic criteria as no added value in the diagnosis of APS has been illustrated so far. The laboratory diagnosis of APS remains challenging. LAC, aCL, aβ2GPI IgG, and IgM should be performed to increase diagnostic efficacy, with an integrated interpretation of all results and an interpretative comment. A close interaction between clinical pathologists and clinicians is mandatory.
PURPOSE OF THE REVIEW: This review focuses on the laboratory tests necessary for the diagnosis of antiphospholipid syndrome (APS). For the interpretation of the results of the tests for antiphospholipid antibodies (aPL), understanding of all pitfalls and interferences is necessary. RECENT FINDINGS: Progress has been made on the standardization of aPL tests and current guidelines for detection of lupus anticoagulant (LAC), anticardiolipin antibodies (aCL), and antibeta2-glycoprotein I antibodies (aβ2GPI) are useful tools. LAC measurement remains a complex procedure with many pitfalls and interference by anticoagulant therapy. Solid phase assays for aCL and aβ2GPI still show inter-assay differences. Measuring LAC, aCL, and aβ2GPI allows making antibody profiles that help in identifying patients at risk. Other aPL, such as antibodies against domain I of beta2-glycoprotein I (aDI) and antiphosphatidylserine-prothrombin (aPS/PT) antibodies, may be useful in risk stratification of APSpatients, but are not included in the current diagnostic criteria as no added value in the diagnosis of APS has been illustrated so far. The laboratory diagnosis of APS remains challenging. LAC, aCL, aβ2GPI IgG, and IgM should be performed to increase diagnostic efficacy, with an integrated interpretation of all results and an interpretative comment. A close interaction between clinical pathologists and clinicians is mandatory.
Authors: Pavla Bradacova; Ludek Slavik; Jana Ulehlova; Adela Skoumalova; Jana Ullrychova; Jana Prochazkova; Antonin Hlusi; Gayane Manukyan; Eva Kriegova Journal: Biomedicines Date: 2021-02-08
Authors: Natalia Egri; Chelsea Bentow; Laura Rubio; Gary L Norman; Susana López-Sañudo; Michael Mahler; Albert Pérez-Isidro; Ricard Cervera; Odette Viñas; Gerard Espinosa; Estíbaliz Ruiz-Ortiz Journal: Front Immunol Date: 2021-10-21 Impact factor: 7.561
Authors: Pavla Bradáčová; Luděk Slavík; Adéla Skoumalová; Jana Úlehlová; Eva Kriegová; Gayane Manukyan; David Friedecký; Barbora Piskláková; Jana Ullrychová; Jana Procházková; Antonín Hluší Journal: Int J Mol Sci Date: 2022-08-11 Impact factor: 6.208